2022 spells change for EU pharmaceutical legislation
European Pharmaceutical Review
JUNE 24, 2022
Meulenbelt highlighted “the desire to have broader launches is very good,” since under the current model, if OMP companies can make a major part of their sales in a limited number of markets they are unlikely to launch elsewhere, limiting patient access. Maarten has significant competition law experience in a variety of sectors.
Let's personalize your content